Abstract: A pharmaceutical dosage system comprising (a) an effective amount of one or more of Doxylamine, an analog thereof, a derivative thereof, a prodrug thereof, a metabolite thereof and/or a salt thereof; (b) an effective amount of one or more of (i) Pyridoxine, (ii) an analog thereof, (iii) a derivative thereof, (iv) a prodrug thereof, (v) a metabolite thereof and (vi) a salt of any of (i)-(v); and (c) an effective amount of one or more compounds of formula (I) wherein R is H, PO3? or The system exhibits an improved pharmacokinetic profile relative to the current Diclectin®/Diclegis® formulation and is useful for example for the alleviation of the symptoms of nausea and vomiting, for example in the case of nausea and vomiting of pregnancy (NVP).

Abstract: A pharmaceutical dosage system comprising (a) an effective amount of one or more of Doxylamine, an analog thereof, a derivative thereof, a prodrug thereof, a metabolite thereof and/or a salt thereof; (b) an effective amount of one or more of (i) Pyridoxine, (ii) an analog thereof, (iii) a derivative thereof, (iv) a prodrug thereof, (v) a metabolite thereof and (vi) a salt of any of (i)-(v); and (c) an effective amount of one or more compounds of formula (I) wherein R is H, PO3- or The system exhibits an improved pharmacokinetic profile relative to the current Diclectin®/Diclegis® formulation and is useful for example for the alleviation of the symptoms of nausea and vomiting, for example in the case of nausea and vomiting of pregnancy (NVP).

Abstract: A dual release oral dosage system/dosage form comprising an immediate release component/composition and a delayed release component/composition is described. Each of the immediate release component/composition and delayed release component/composition comprises one or more of doxylamine, an analog thereof, a derivative thereof, a prodrug thereof, a metabolite thereof and/or a salt thereof, and one or more of pyridoxine, a salt thereof, a metabolite thereof and/or a salt of the metabolite. The dual release oral dosage system/dosage form exhibits an improved pharmacokinetic profile relative to the current Diclectin® formulation and is useful for example for the alleviation of the symptoms of nausea and vomiting, for example in the case of nausea and vomiting in pregnancy (NVP).

Abstract: One illustrative computing device disclosed herein includes a sensor configured to detect a user interaction with a physical object and transmit a sensor signal associated with the user interaction. The illustrative computing device also includes a processor in communication with the sensor, the processor configured to: receive the sensor signal; determine a characteristic of the physical object based on the sensor signal; determine a haptic effect associated with the characteristic; and transmit a haptic signal associated with the haptic effect. The illustrative computing device further includes a haptic output device in communication with the processor, the haptic output device configured to receive the haptic signal and output the haptic effect.

Abstract: One illustrative computing device disclosed herein includes a sensor configured to detect a user interaction with a physical object and transmit a sensor signal associated with the user interaction. The illustrative computing device also includes a processor in communication with the sensor, the processor configured to: receive the sensor signal; determine a characteristic of the physical object based on the sensor signal; and determine a function based at least in part on the user interaction and the characteristic. The processor is also configured to determine a haptic effect associated with the function; and transmit a haptic signal associated with the haptic effect. The illustrative computing device further includes a haptic output device in communication with the processor, the haptic output device configured to receive the haptic signal and output the haptic effect.

Abstract: A pharmaceutical dosage system comprising (a) an effective amount of one or more of Doxylamine, an analog thereof, a derivative thereof, a prodrug thereof, a metabolite thereof and/or a salt thereof; (b) an effective amount of one or more of (i) Pyridoxine, (ii) an analog thereof, (iii) a derivative thereof, (iv) a prodrug thereof, (v) a metabolite thereof and (vi) a salt of any of (i)-(v); and (c) an effective amount of one or more compounds of formula (I) wherein R is H, PO3 or. The system exhibits an improved pharmacokinetic profile relative to the current Diclectin®/Diclegis® formulation and is useful for example for the alleviation of the symptoms of nausea and vomiting, for example in the case of nausea and vomiting of pregnancy (NVP).

Abstract: A system that generates haptic effects using an actuator sends a haptic effect definition to the actuator to cause a haptic effect corresponding to the haptic effect definition to be played. While the haptic effect is playing, the system processes the haptic effect definition. The processing includes adjusting a force value of the haptic effect definition based on an estimate or measurement of a current state of the actuator.

Abstract: Method for encoding a series of symbols using several models of the arithmetic or range coder type and including steps where: each model is associated with a belonging criterion, the series is run through in order to determine, for each symbol, the encoding model to which it belongs, according to the criteria; then a probability of occurrence of each symbol in the corresponding model is determined; then the series is run through by encoding each symbol successively; and a file is formed from the code thus obtained.

Abstract: A solid oral dosage form comprising a core comprising a doxylamine component and a pyridoxine component coated with an enteric coating is disclosed. The solid oral dosage form further comprises two active ingredient-containing coatings surrounding the enteric coating, the active ingredient-containing coatings being separated from one another by an intermediate coating, and one of the two active ingredient-containing coatings comprising a doxylamine component and being free of a pyridoxine component, and the other of the two active ingredient-containing coatings comprising a pyridoxine component and being free of doxylamine component. Uses of the solid oral dosage form for the alleviation of the symptoms of nausea and vomiting, for example in the case of nausea and vomiting of pregnancy (NVP), are also disclosed.

Abstract: A dual release oral dosage system/dosage form comprising an immediate release component/composition and a delayed release component/composition is described. Each of the immediate release component/composition and delayed release component/composition comprises one or more of doxylamine, an analog thereof, a derivative thereof, a prodrug thereof, a metabolite thereof and/or a salt thereof, and one or more of pyridoxine, a salt thereof, a metabolite thereof and/or a salt of the metabolite. The dual release oral dosage system/dosage form exhibits an improved pharmacokinetic profile relative to the current Diclectin® formulation and is useful for example for the alleviation of the symptoms of nausea and vomiting, for example in the case of nausea and vomiting in pregnancy (NVP).

Abstract: A system that generates haptic effects using an actuator receives a haptic effect definition that defines a haptic effect. The system pre-processes the haptic effect definition by determining if the actuator is capable of playing the haptic effect. The system then post-processes the haptic effect definition by adjusting a force value based on an estimate or measurement of a state of the actuator during a playing of the haptic effect.

Abstract: A system is provided that generates haptic effects using a haptic output device. The system receives a haptic effect definition that defines the haptic effect. The system determines, at run-time, whether the haptic effect definition will produce an output effect as designed/desired using the haptic output device. When it is determined that the haptic effect definition will not produce the output effect as designed/desired, the system modifies, at run-time, the haptic effect definition to ensure that the haptic effect produced corresponds to the designed/desired haptic effect.

Abstract: Method and apparatus for the digital encoding of a first raw file, the method includes: a first step of capturing the raw file, the raw file being an audio and/or image and/or video file; a second step of encoding the captured raw file into a second file, in a proprietary format (P); then, a third step for re-encoding the second file into a third file in a compatible format (C).

Abstract: A method for reversible coding of an image, including extracting compression information from an image compressed in an original format, at least partly decompressing the compressed image into an intermediate at least partly decompressed image, re-encoding the intermediate image into a re-encoded image, and preferably associating in a same file, the re-encoded image with compression information.

Abstract: A dual release oral dosage system/dosage form comprising an immediate release component/composition and a delayed release component/composition is described. Each of the immediate release component/composition and delayed release component/composition comprises one or more of doxylamine, an analog thereof, a derivative thereof, a prodrug thereof, a metabolite thereof and/or a salt thereof, and one or more of pyridoxine, a salt thereof, a metabolite thereof and/or a salt of the metabolite. The dual release oral dosage system/dosage form exhibits an improved pharmacokinetic profile relative to the current Diclectin® formulation and is useful for example for the alleviation of the symptoms of nausea and vomiting, for example in the case of nausea and vomiting in pregnancy (NVP).

Abstract: A method for compressing a stream by means of a codec (C), provided for assigning to a compressed stream an encoding throughput (Q) measured in bits per second, using a pre-filter (X1) replacing in the header (T1) of the original stream, the restoration frequency (R) with a frequency equal to the product (R×K) of the restoration frequency (R) by a coefficient (K) and then for retransmitting the thereby filtered stream (FX1) to the codec; the post-filter (X2) replacing the restoration frequency (R) into the header (TX2) of a stream (FX2) resulting from the encoding of the pre-filtered stream (FX1) by the codec C.

Abstract: A system that generates haptic effects using an actuator receives a haptic effect definition that defines a haptic effect. The system pre-processes the haptic effect definition by determining if the actuator is capable of playing the haptic effect. The system then post-processes the haptic effect definition by adjusting a force value based on an estimate or measurement of a state of the actuator during a playing of the haptic effect.

Abstract: A pharmaceutical dosage system comprising (a) an effective amount of one or more of Doxylamine, an analog thereof, a derivative thereof, a prodrug thereof, a metabolite thereof and/or a salt thereof; (b) an effective amount of one or more of (i) Pyridoxine, (ii) an analog thereof, (iii) a derivative thereof, (iv) a prodrug thereof, (v) a metabolite thereof and (vi) a salt of any of (i)-(v); and (c) an effective amount of one or more compounds of formula (I) wherein R is H, PO3? or The system exhibits an improved pharmacokinetic profile relative to the current Diclectin®/Diclegis® formulation and is useful for example for the alleviation of the symptoms of nausea and vomiting, for example in the case of nausea and vomiting of pregnancy (NVP).

Abstract: A pharmaceutical dosage system comprising (a) an effective amount of one or more of Doxylamine, an analog thereof, a derivative thereof, a prodrug thereof, a metabolite thereof and/or a salt thereof; (b) an effective amount of one or more of (i) Pyridoxine, (ii) an analog thereof, (iii) a derivative thereof, (iv) a prodrug thereof, (v) a metabolite thereof and (vi) a salt of any of (i)-(v); and (c) an effective amount of one or more compounds of formula (I) wherein R is H, PO3? or The system exhibits an improved pharmacokinetic profile relative to the current Diclectin®/Diclegis® formulation and is useful for example for the alleviation of the symptoms of nausea and vomiting, for example in the case of nausea and vomiting of pregnancy (NVP).

Abstract: A method is disclosed for compressing a sequence of initial digital values into a compressed sequence of compressed values, intending to restore these values into a decompressed sequence of decompressed values. For a first initial value of the sequence, the compressed value of the first initial value is equal to the first initial value and the decompressed value of the compressed value of the first initial value is equal to the first initial value.